SUMMIT THERAPEUTICS INC (SMMT) Stock News
NASDAQ:SMMT - Nasdaq - US86627T1088 - Common Stock - Currency: USD
SMMT Latest News, Press Relases and Analysis
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
Intrigued by the market activity one hour before the close of the markets on Friday? Uncover the key winners and losers of today's session in our insightful analysis.
Top stock movements in today's session.
Stay up-to-date with the latest market trends in the middle of the day on Friday. Explore the top gainers and losers during today's session in our detailed report.
Can Summit Therapeutics Stock Double Your Money?
Can Summit Therapeutics Stock Double Your Money?
The stock's high price tag could be a problem for investors looking for a big return. Summit Therapeutics (NASDAQ: SMMT) has more than just a potential blockbuster cancer drug in its portfolio. This has investors excited that Summit may be one of the next big healthcare companies in the world.
Wall Street Analysts Predict a 33.4% Upside in Summit Therapeutics (SMMT): Here's What You Should Know
The consensus price target hints at a 33.4% upside potential for Summit Therapeutics (SMMT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Duolingo, CoreWeave And DexCom Are Among Top 10 Large-Cap Gainers Last Week (Apr 28-May 2): Are The Others In Your Portfolio?
Top performing large-cap stocks in the last week: DUOL, CRWV, THC, CARR, SMMT, AUR, ANET, TT, DXCM, XPO. Most had positive financial results and raised guidance.
How the stock market made back all its losses after Trump escalated the trade war
It felt much longer, but the U.S. stock market needed just a few weeks to roar all the way back to where it was on President Donald Trump's “Liberation Day.” Within just four days, the S&P 500 fell about 12%, and the Dow Jones Industrial Average lost nearly 4,600 points, or about 11%. This past Friday, though, the S&P 500 rallied 1.5% for a ninth straight gain and pulled back to where it was on April 2.
Berkshire investors anticipate new era as Buffett hands over baton
OMAHA, Nebraska (Reuters) -Berkshire Hathaway shareholders mourning the departure of legendary investor Warren Buffett anticipate the conglomerate he built over 60 years will retain its long-term focus and culture but worry about the loss of Buffett's vision and star power. Following Buffett's surprise announcement on Saturday that he would step down as chief executive by the end of the year, Berkshire shareholders and fans said the Omaha, Nebraska-based company will remain in good hands once Vice Chairman Greg Abel takes the top job. But they said it remains unclear how the $1.16 trillion conglomerate, which has 189 operating businesses, $264 billion of stocks and $348 billion of cash, will fare after the man so intertwined with it leaves the stage.
Why DexCom Inc. (DXCM) Soared Last Week
We recently published a list of These 10 Firms Soared Last Week, Here’s Why. In this article, we are going to take a look at where DexCom Inc. (NASDAQ:DXCM) stands against other firms that soared last week. The past trading week saw a more calm, generally optimistic, market environment amid the temporary pause in tit-for-tat […]
Why Summit Therapeutics Inc. (SMMT) Soared Last Week
We recently published a list of These 10 Firms Soared Last Week, Here’s Why. In this article, we are going to take a look at where Summit Therapeutics Inc. (NASDAQ:SMMT) stands against other firms that soared last week. The past trading week saw a more calm, generally optimistic, market environment amid the temporary pause in tit-for-tat […]
Buffett passes the torch — here’s what Berkshire loyalists should know, from a longtime insider
Buffett’s CEO successor Greg Abel may bring a change in style, greater collaboration.
Summit Therapeutics Q1 Loss Narrower Than Expected, Sales Nil
SMMT's first-quarter earnings outpace estimates. The company also provides updates on its pipeline.
This Soaring Stock Just Delivered More Good News. Time to Buy?
Meet This Monster Dividend Stock That Continues to Crush the Market in 2025
British American Tobacco has a 7% dividend yield. Price hikes and growth in smokeless nicotine products should drive earnings growth in the years ahead. The financials indicate that British American Tobacco can keep growing its dividend per share in the future.
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025
Should You Buy, Sell or Hold MRK Stock After Q1 Earnings Beat?
We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors may exit the stock.
Akeso survival data for ivonescimab misses expectations, STAT says
While Akeso (AKESF) and Summit Therapeutics’ (SMMT) ivonescimab, a rival to Merck’s (MRK) Keytruda, won approval in China this week, the data on patient survival did not meet analyst expectations, Jonathan Wosen of STAT reports. In its submission to regulators, Akeso included data on patient survival, disclosing that an interim analysis following 157 patient deaths found that participants on ivonescimab had a roughly 22% reduced risk of death, with a hazard ratio of 0.784, a company spokesperson
4 Pipeline Stocks to Buy With $1,000 and Hold Forever
Pipeline companies remain well positioned despite the current disruption in the energy markets. At the same time, demand for natural gas is growing. This is coming from the increased power consumption stemming from artificial intelligence (AI), as well as from export demand from Mexico and for LNG (liquified natural gas) to Asia and Europe.
Summit Therapeutics Stock Slumps After Partner Akeso Gets FDA Nod For Cancer Drug: Retail’s Optimistic
The company’s lead candidate, ivonescimab, aimed at treating certain cancers, was discovered by Akeso and is currently in multiple late-stage clinical trials.
Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025
Could Applied Digital Be the Best Under-The-Radar AI Stock?
The data center operator deserves a bit more attention.
Summit Therapeutics Retail Traders Stoked As Stock Surges On Promising Cancer Drug Trial
The study was conducted across multiple centers in China, comparing ivonescimab plus chemotherapy against tislelizumab (marketed as Tevimbra by BeiGene) plus chemotherapy.
Why Summit Therapeutics Rocketed Double-Digits Today
Shares of lung cancer biotech Summit Therapeutics (NASDAQ: SMMT) rocketed 14.7% on Wednesday as of 1:45 p.m. ET. Summit disclosed some preliminary results of its HARMONi-6 trial, conducted in partnership with Akeso. In the trial, Summit's antibody drug ivonescimab was administered along with platinum-based chemotherapy against the current standard of care, tislelizumab, which is made by BeiGene (NASDAQ: BGNE), in patients with locally advanced or metastatic squamous non-small cell lung cancer (NSCLC).
BioNTech Surges On Summit's Coattails. But Can They Take On Merck?
BioNTech is on the rise after Summit Therapeutics unveiled promising results for its PD-1- and VEGF-blocking drug.
This Company's Co-CEOs Just Bought More Shares. Should You?
Nobody has more information about a company than its insiders, especially its executive management team. On April 8, Summit Therapeutics' co-CEOs, Robert Duggan and Maky Zanganeh, each exercised warrants, financial instruments that grant their holders the right (but not the obligation) to acquire a company's shares at a predetermined price before a particular date. Do Summit Therapeutics' prospects -- beyond this recent development -- justify investing in the stock today?